394653-44-2

Basic information

• Product Name: (-)-3-oxetanylglycine methyl ester
• Synonyms: 3-Oxetaneacetic acid, α-aMino-, Methyl ester, (-)-
• CAS NO: 394653-44-2
• Molecular Formula: C₆H₁₁NO₃
• Molecular Weight: 145
• Mol File: 394653-44-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (-)-3-oxetanylglycine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-3-oxetanylglycine methyl ester(394653-44-2)
• EPA Substance Registry System: (-)-3-oxetanylglycine methyl ester(394653-44-2)

Safety Data

• Hazardous Substances Data: 394653-44-2(Hazardous Substances Data)

Usage

Description

(-)-3-oxetanylglycine methyl ester is a chemical compound with the molecular formula C6H11NO4. It is a derivative of glycine, an essential amino acid, known for its ability to form a three-membered ring called an oxetane. This unique structure makes it valuable for creating cyclic structures in the development of new drugs and chemical products. Its methyl ester functional group also provides reactivity and versatility for use in various chemical reactions, making it a promising building block in the production of a wide range of important chemical compounds, particularly in the pharmaceutical and biotechnology industries.

Uses

Used in Pharmaceutical Industry:
(-)-3-oxetanylglycine methyl ester is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to form cyclic structures and its reactivity in chemical reactions. This allows for the development of innovative drugs with improved properties and therapeutic effects.
Used in Organic Compounds Synthesis:
(-)-3-oxetanylglycine methyl ester is used as a versatile building block in the synthesis of organic compounds due to its unique oxetane ring and methyl ester functional group. This enables the creation of a wide range of chemical products with diverse applications in various industries.
Used in Drug Development:
(-)-3-oxetanylglycine methyl ester is used as a valuable component in drug development for its potential to enhance the properties of new drugs. Its incorporation into drug molecules can lead to improved efficacy, selectivity, and reduced side effects, contributing to the advancement of novel therapeutic agents.

Upstream product

• 394653-39-5 N-benzyloxycarbonyl-α,β-didehydro-(3-oxetanyl)glycine methyl ester 

Downstream Products

• 1255717-04-4 methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 
• 1408074-43-0 (R)-2-((tert-butoxycarbonyl)amino)-2-(oxetan-3-yl)acetic acid 
• 1616889-73-6 C₁₃H₁₅NO₅ 
• 1213783-62-0 (S)-methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 
• 1270019-87-8 2-amino-2-(oxetan-3-yl)acetic acid 

Relevant articles and documents

Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives

L-amino alcohol derivatives exhibited high antifungal activity, but the metabolic stability of human liver microsomes in vitro was poor, and the half-life of optimal compound 5 was less than 5 min. To improve the metabolic properties of the compounds, the scaffold hopping strategy was adopted and a series of antifungal compounds with a dihydrooxazole scaffold was designed and synthesized. Compounds A33-A38 substituted with 4-phenyl group on dihydrooxazole ring exhibited excellent antifungal activities against C. albicans, C. tropicalis and C. krusei, with MIC values in the range of 0.03–0.25 μg/mL. In addition, the metabolic stability of compounds A33 and A34 in human liver microsomes in vitro was improved significantly, with the half-life greater than 145 min and the half-life of 59.1 min, respectively. Moreover, pharmacokinetic studies in SD rats showed that A33 exhibited favourable pharmacokinetic properties, with a bioavailability of 77.69%, and half-life (intravenous administration) of 9.35 h, indicating that A33 is worthy of further study.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.